Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: miRNA therapeutics - Synlogic

Next Previous
Drug Profile

Research programme: miRNA therapeutics - Synlogic

Alternative Names: let-7; let-7 mimic; let-7b; let-7c; let-7g; miR-101; miR-192; miR-215; miR-Rx01; miR-Rx02; miR-Rx03; miR-Rx04; miR-Rx05; miR-Rx06; miR-Rx07; miR-Rx16; miR-Rx16 mimic; miR-Rxlet-7; Tumour suppressor microRNAs - Synlogic

Latest Information Update: 08 Apr 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Asuragen
  • Developer Mirna Therapeutics; Synlogic; University of Texas M. D. Anderson Cancer Center
  • Class MicroRNAs
  • Mechanism of Action Oncogene protein inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Bladder cancer; Colorectal cancer; Gastric cancer; Haematological malignancies; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 06 Apr 2021 Asuragen has been acquired by Bio-Techne
  • 28 Apr 2020 No recent reports of development identified for preclinical development in Bladder-cancer in USA
  • 28 Apr 2020 No recent reports of development identified for preclinical development in Gastric-cancer in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top